Healthcare / BiotechnologyNasdaqCM
$9.66
-1.16 (-10.76%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-24.4M · quality 68.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$873M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-55.3%
↓Gross Margin
N/A
•Debt/Equity
0.18
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.77x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-42.6M · FCF $-32.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-42.6M | $-42.6M | $-31.8M | $-29.2M | $-33.8M |
| EBITDA | $-40.9M | $-40.9M | $-30.3M | $-28.0M | $-32.8M |
| EPS | — | — | -0.45 | -0.42 | -0.53 |
| Balance Sheet | |||||
| Debt/Equity | 0.18 | 0.18 | 0.20 | 0.16 | 0.05 |
| Current Ratio | 7.79 | 7.79 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-32.8M | $-32.8M | $-22.0M | $-24.4M | $-24.8M |
| Returns | |||||
| ROE | -55.3% | -55.3% | -50.7% | -34.5% | -32.0% |
| Valuation | |||||
| P/B | 11.03 | 11.03 | 3.49 | 2.60 | 2.01 |
| Growth & Yield | |||||
| EPS Growth | — | — | -7.1% | 20.8% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+223.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.45 → n/d
Residual
+223.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.